Summary
Six healthy volunteers received single iv and oral doses of 2-[p-(1-oxo-2-isoindolinyl)phenyl] butyric acid 100 mg (indobufen; K 3920), an inhibitor of platelet aggregation. Plasma levels and urinary excretion of the drug were determined by GLC. Collagen-induced platelet aggregation was assessed turbidimetrically at various intervals after administration. The plasma half-life of the drug was 7–8 h and more than 70% of the administered dose was recovered within 48 h in urine, as unchanged drug and as the glucuronide of indobufen. After oral administration of tablets of two different formulations, the drug was completely absorbed, but one formulation showed faster absorption. The maximal inhibitory effect on platelet aggregation was observed 1 to 4 h after iv administration, and it had decreased by 8 h. After tablets, peak effect and the time of the peak were similar, but activity was significantly prolonged, in accordance with the higher plasma levels found at 8 h. The data suggest that the effect of indobufen on platelets is reversible, and that for this drug platelets behave as a compartment that slowly equilibrates with plasma.
Similar content being viewed by others
References
Bergamaschi, M., Ceserani, R. Pierucci, L., Pogliani, E., Spelta, A.: K 3920: A new inhibitor of platelet aggregation. Communication at the 4th Meeting of European and African Division of Intern. Society of Haematology, Istanbul, 5–9 September 1977, No° 662
Bergamaschi, M., Spelta, A., Pogliani, E., Pierucci, L.: Effetto di un nuovo agente antiaggregante (K 3920) sulla coagulazione intravascolare nell'animale. Atti XXV Congr. Naz. Soc. Italiana Ematologia, Milano, 3–6 September, 1975, pp. 332–340
Born, G.V.R.: Quantitative investigations into the aggregation of blood platelets. J. Physiol. (Lond.)162, 67–68 (1962)
Dunnett, C.W.: A multiple comparison procedure for comparing several treatments with a control. Am. Stat. Ass. J.50, 1096–1121 (1955)
Fortunato, G., Coccheri, S.: Effect of K 3920, a new antiplatelet agent, after oral administration at two dose levels. Communication at the 5th International Congress on Thromboembolism, Bologna, May 29–June 2, 1978; Abstract Book, p. 239
Jonker, J.J.C., Pannebakker, M.A.G., Boer, A.C., Reitsma, D.J., den Ottolander, G.J.H.: Pilot study on K 3920, inhibitor of platelet aggregation, in deep venous thrombosis of patients with heart failure. Communication at the 5th International Congress on Thromboembolism, Bologna, May 29–June 2, 1978; Abstract Book, p. 243
Pogliani, E., Corvi, G., Fuccella, L.M.: Preliminary human pharmacology studies on the inhibition of platelet aggregation by K 3920. Communication at the 4th Meeting of European and African Division of International Society of Haematology, Istanbul, 5–9 September 1977, Abstract Nc 661
Author information
Authors and Affiliations
Additional information
A preliminary account of this study was given at the 4th Meeting of the European and African Division of the International Society of Haematology, Istanbul, 5–9 September 1977.
Rights and permissions
About this article
Cite this article
Fuccella, L.M., Corvi, G., Moro, E. et al. Pharmacokinetic, bioavailability and pharmacodynamic study of indobufen (K 3920), an inhibitor of platelet aggregation, after a single dose in man. Eur J Clin Pharmacol 15, 323–327 (1979). https://doi.org/10.1007/BF00558435
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558435